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Purpose: It has been suggested that constitutive up-regulation of cyclooxygenase (COX)-2 is associated with resistance to 
apoptosis, increased angiogenesis, and increased tumor invasiveness in various cancers including colon cancer. There are 
many factors involved in the resistance to 5-fluorouracil (5-FU) in colon cancer. However, little is known about the role of 
COX-2 in acquired resistance to 5-FU in colon cancer. Methods: Hence we investigated whether COX-2 contribute to ac-
quired resistance to 5-FU in colon cancer cells, using cytotoxicity assay for cell survival, reverse transcription-polymerase 
chain reaction (RT-PCR) for vascular endothelial growth factor (VEGF), quantitative RT-PCR for COX-1 and COX-2, and en-
zyme-linked immunosorbent assay for PGE2. Results: The 5-FU resistant colon cancer cells, SNU-C5/5FUR, showed in-
creased expression of COX-2, prostaglandin E2 (PGE2), and VEGF, compared to its parental cell (SNU-C5). By treatment with 
meloxicam, the expression of PGE2 and VEGF was reduced significantly in the resistant cells, but not in the parent cells. 
Conclusion: These results demonstrate that COX-2 derived PGE2 is up-regulated and COX-2 inhibitor may have an anti-an-
giogenic effect in the colon cancer cells resistant to 5-FU. 
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INTRODUCTION
5-Fluorouracil (5-FU) is a widely used chemothera-
peutic agent that inhibits cancer cell growth and initiates 
apoptosis by targeting thymidylate synthase (TS), and by 
direct incorporation of 5-FU metabolites into DNA and 
RNA [1]. 5-FU-based chemotherapy improves the overall 
and disease-free survival of patients with solid cancers, in-
cluding colorectal cancer. However, de novo and acquired 
chemoresistance are major obstacles to the success of 
5-FU-based chemotherapy. The overexpression of TS has 
been shown to be a major 5-FU resistance-inducing factor 
[2]. However, the overexpression of TS does not account 
for all non-responding tumors in colorectal cancer pa-
tients treated with 5-FU [3]. High expression levels of di-
hydropyrimidine dehydrogenase (DPD), the genetic sta-
tus of p53, NF-kB, DNA mismatch-repair genes, and cell 
cycle disturbance have also been reported to be associated Cheol Hee Choi, et al.
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with 5-FU resistance [3-7]. Thus, the mechanisms of resist-
ance to 5-FU are believed to be multi-factorial. 
  The up-regulation of cyclooxygenase (COX)-2 ex-
pression is an early and key oncogenic event in human co-
lon neoplasia, and occurs in 85% of colon cancers and in 
50% of colon adenomas [8]. It has also been suggested that 
the overexpression of COX-2 in colorectal cancer is asso-
ciated with tumor growth, angiogenesis, lymphatic in-
vasion, and metastasis [9]. Nonsteroidal anti-inflam-
matory drugs (NSAIDs) targeting COX-2 have been 
shown to directly shrink colon adenomas in some patients 
and to mediate cancer cell apoptosis [10,11]. Similarly, in 
mice, the genetic inactivation of COX-2 blocks murine in-
testinal adenoma development [12,13]. Most actions of 
COX-2 are known to be mediated by prostaglandin E2 
(PGE2). Furthermore, it has been reported that the anti-
tumor effects of 5-FU are increased when it is co-treated 
with COX-2 inhibitors [14,15]. However, little is known 
about the role of COX-2 in acquired resistance to 5-FU in 
colon cancer cells.
In the present study, we investigated whether COX- 
2-derived PGE2 contributes to acquired resistance to 5-FU 
in colon cancer cells. 
METHODS
Cell culture
The SNU-C5 colon cancer cell line (KCLB no. 0000C5) 
was obtained from the Korean Cell Line Bank (Seoul, 
Korea) and cultured at 37
oC in a 5% CO2 atmosphere using 
Roswell Park Memorial Institute (RPMI) 1640 medium 
(Invitrogen, Gland Island, NY, USA) with 10% heat in-
activated fetal bovine serum (FBS, Sigma-Aldrich Co., St. 
Louis, MO, USA). The 5-fluorouracil-resistant SNU-C5 
subline, SNU-C5/5FUR, was selected from its parental cell 
line, SNU-C5, after chronic exposure to an intermittent 
dose schedule of 5-FU (Sigma-Aldrich Co.) in order to fa-
cilitate the expression of the resistant phenotype. 5-FU was 
initially added at 1 × IC50 (50% inhibitory concentration, 
17.5 μM), and subsequently increased at a rate of 50%. 
Finally, the cells were cultured in a fixed 5-FU concen-
tration (140 μM) [16]. When the sensitivities of SNU-C5 
and SNU-C5/5FUR cells to 5-FU were determined using 
3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assays, the IC50 values of SNU-C5 and 
SNU-C5/5FUR cells were 7.8 μM and 337.4 μM, respec-
tively, i.e., SNU-C5/5FUR cells were 43.6 times more re-
sistant to 5-FU than SNU-C5 cells.  
Cytotoxicity assays
The in vitro cytotoxicities of 5-FU and/or meloxicam 
(COX-2 inhibitor, Sigma-Aldrich Co.) were determined by 
using MTT assays [17]. Ninety-μL aliquots of cell suspen-
sions, at 1 × 10
5 cells/mL in a RPMI 1640 medium contain-
ing 10% FBS, were seeded into a 96-well microplate con-
taining 10 μL/well of a drug. Wells containing no drugs 
were used as cell viability control. A stock solution of 5 
mg/mL of MTT (Sigma-Aldrich Co.) was prepared in nor-
mal saline and then stored at -20
oC. After cells had been in-
cubated at 37
oC for 3 days, an aliquot of 10 μL of MTT sol-
ution was added to each well, shaken for 1 minute, and in-
cubated for 4 hours. Formazan crystals were dissolved 
with dimethylsulfoxide. The optical density of the wells 
was measured using a microplate reader at a wavelength 
of 540 nm. The IC50 of a drug was defined as the concen-
tration that caused a 50% reduction in cell number versus 
the untreated control. IC50 v a l u e s  w e r e  d i r e c t l y  d e t e r -
mined from semi-logarithmic dose-response curves. All 
experiments were carried out at least in triplicate. 
Determination of mRNA levels by quantitative re-
verse transcription-polymerase chain reaction (RT- 
PCR)
Quantitative real-time RT- PCR for COX-1 and COX-2
Extraction of mRNA from SNU-C5/WT and SNU-C5/ 
5FUR was performed using the RNeasy protocol (Qiagen, 
Hilden, Germany). One microgram of total RNA was re-
verse transcribed into cDNA in a volume of 20 μL using 
avian myeloma leukemia virus reverse transcriptase and 
oligo dT primers (Promega, Madison, WI, USA), accord-
ing to the manufacturer's instructions. Real-time PCR 
measures of COX-1, COX-2, and b-actin cDNA expression 
were obtained using a Light Cycler (Roche Diagnostics, 
Mannheim, Germany) with a Fast Start DNA Master SYBR Up-regulation of COX-2 derived PGE2 in 5-FU resistant colon cancer
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Green I Kit (Roche Diagnostics). To verify amplification 
products, PCR products were analyzed on 2% agarose gel 
and stained with ethidium bromide. The sequences of the 
primers used were as follows: for β-actin, 5'-GACTATG-
ACTTAGTTGCGTTA-3' and 5'-GTTGAACTCTCTACA-
TACTTCCG-3'; for COX-2, 5'-ATGATCTACCCTCCT-
CAA-3' and 5'-GAACAACTGCTCATCAC-3'; for COX-1, 
5'-CATCAAGATGTACGTGGT-3' and 5'-GGAGTAGAC-
GAAGCCC-3'. Each reaction (20 μL) contained 4 μL cDNA 
(5-fold dilution), 2.5 mM MgCl2, 10 pmol of each primer 
and 2 μL of Fast Starter Mix (containing buffer, dNTPs, 
SYBR Green dye and Tag polymerase). Target genes were 
amplified using the following conditions: pre-denaturing 
at 95
oC for 10 minutes, 40 cycles of denaturing at 95
oC for 
15 seconds, annealing for COX-2 at 59
oC; COX-1 at 60
oC; β- ac-
tin at 55
oC for 5 seconds, and extension at 72
oC for 7 sec-
onds (β-actin for 21 seconds). Melting curve analysis was 
performed to confirm the production of single PCR pro-
ducts. Negative controls without template were produced 
for each run. Gene expression values (relative mRNA lev-
els) are expressed as ratios (differences between cycle 
threshold values) between the gene of interest (COX-1, 
COX-2 mRNA) and β-actin (internal control). These pro-
vided a normalization factor for the amount of RNA iso-
lated from a given specimen. Analysis of data was per-
formed using Light Cycler software version 4.0. 
RT-PCR analysis for vascular endothelial growth 
factor (VEGF)
RT-PCR was used to analyze the expression of VEGF 
and β-actin mRNAs. One microgram of total RNA was re-
verse transcribed into cDNA in a volume of 20 μL contain-
ing Taq polymerase and 10 pmole of each primer in a 
GeneAmp PCR2400 (Perkin-Elmer, Boston, MA, USA). To 
confirm amplification products, PCRs were analyzed on 
2% agarose gel and stained with ethidium bromide. Gels 
were documented using a Kodak Imaging Station 4000 
MM (Eastman Kodak, Rochester, NY, USA) and digitized 
using UN-SCAN-IT software (SilK Scientific, Orem, UT, 
USA). The sequences of the primers used were follows: for 
β-actin, 5'-GACTATGACTTAGTTGCGTTA-3' and 5'- 
GTTGAACTCTCTACATACTTCCG-3'; for VEGF, 5'-AYG-
CGGATCAAACCTCACCAAG-3' and 5'-ACAGCAGC-
GGGCACCAAC-3'. Each reaction (20 μL) contained 1.25 
μL cDNA, 2.5 mM MgCl2, 10  pmol of each primer and Taq 
polymerase (Perkin-Elmer-Cetus, Norwalk, CT, USA). 
The amplification of target genes were as follows: pre-de-
naturing at 94
oC for 5 minutes, 35 cycles of denaturing at 
94
oC for 30 seconds, annealing for VEGF at 62
oC (β-actin at 
55°C) for 30 seconds, and extension at 72
oC for 1 minute 
(β-actin for 21 seconds). 
Enzyme-linked immunosorbent assay (ELISA) for 
PGE2
PGE2 levels in culture media were measured by using a 
general radioimmunoassay procedure adapted from 
Cetta and Goetz [18]. Briefly, in preliminary studies, pros-
taglandin was recovered from culture media using ex-
traction fluid (ethyl acetate:isopropanol:0.05 N HCl = 3: 
3:1); the recovery rate was relatively constant (92 ± 3%, n = 
9). When PGE2 was assayed in increasing aliquots of un-
extracted medium (25, 50 and 100 μL), potency estimates 
were parallel to a linearly transformed dose response 
curve. Accordingly, medium samples were assayed di-
rectly without extraction. Samples were quantified using a 
liquid scintillation analyzer. Duplicate hormone stand-
ards (5 to 1,000 pg) were included in each assay. The be-
tween- and within-assay variation coefficients for PGE2 
were 7.3% and 6.5%, respectively.
Statistical analysis 
Statistically significant differences between multiple 
groups were analyzed using the Student’s t-test or the 
paired Student’s t-test (SPSS version 12.0, SPSS Inc., 
Chicago, IL, USA). The level of significance was set at P ＜ 
0.05 in all cases.
RESULTS
Expression of COX-1, COX-2 in SNU-C5 and 
SNU-C5/5FUR cells 
By quantitative RT-PCR, the expression levels of COX-1 
and COX-2 were significantly higher in SNU-C5/5FUR 
than in SNU-C5. Also the ratio of COX-2 to COX-1 was 
higher in the resistant cells than in the parental cells (Fig. 1).Cheol Hee Choi, et al.
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Fig. 1. mRNA expression patterns of cyclooxygenase (COX)-2 in SNU-C5 and SNU-C5/5FUR determined by quantitative reverse 
transcription- polymerase chain reaction. (A) Significant difference in the ratio of COX-2/β-actin between SNU-C5 and SNU-C5/5FUR (P = 
0.000727)
a), (B) Significant difference in the ratio COX-2/COX-1 between SNU-C5 and SNU-C5/5FUR (P = 0.00117).
a)
Fig. 2. Comparison of prostaglandin E2 (PGE2) levels between 
SNU-C5 and SNU-C5/5FUR. PGE2 levels present in the supernatant 
of the culture medium were determined by enzyme-linked im-
munosorbent assay using PGE2 monoclonal antibody.
 a)Compare 
PGE2 levels between SNU-C5 and SNU-C5/5FUR at basal state. 
b)Compare PGE2 levels after 12 hours treatment of meloxicam (10 
μM) with control in SNU-C5/5FUR. 
c)Compare PGE2 levels after 
meloxicam (100 μM) with control in SNU-C5/5FUR, all of which 
have P-values less than 0.01.
Up-regulation of PGE2 levels in SNU-C5/5FUR 
and inhibitory effect of meloxicam on PGE2  syn-
thesis
 PGE2 levels present in culture media supernatants after 
incubation for 12 hours were determined by ELISA. For 
untreated cells, PGE2 levels were significantly higher in 
SNU-C5/5FUR than in SNU-C5 (P ＜  0.01). After treatment 
with meloxicam, PGE2 levels were significantly and 
dose-dependently reduced in SNU-C5/5FUR cells (P ＜ 
0.01), but not in SNU-C5 cells (Fig. 2).  
Cytotoxicities of SNU-C5 and SNU-C5/5FUR to 5- 
FU and/or meloxicam 
To investigate whether or not meloxicam can potentiate 
the cytotoxic effect of 5-FU in the two cell lines, MTT as-
says were conducted. Meloxicam did not have any poten-
tiating effect on 5-FU sensitivity in either cell line (Fig. 3).
Up-regulation of VEGF mRNA expression in 
SNU- C5/5FUR and the inhibitory effect of melox-
i c a m  o n  V E G F  m R N A  e x p r e s s i o n  
Despite the above-mentioned PGE2 level increases in 
SNU-C5/5FUR cells, meloxicam showed little effect on 
overcoming resistance to 5-FU in cell culture. Thus, we in-
vestigated VEGF expression, as VEGF is the most power-
ful stimulator for angiogenesis, and is required for tumor 
growth and metastasis. VEGF mRNA levels in untreated 
SNU-C5/5FUR cells were higher than that in SNU-C5 cells, 
Ten μM to 500 μM of meloxicam down-regulated these lev-
els in SNU-C5/5FUR cells in a dose-dependent manner. 
However, paradoxically meloxicam dose-dependently in-
creased VEGF mRNA levels in SNU-C5/WT cells (Fig. 4). Up-regulation of COX-2 derived PGE2 in 5-FU resistant colon cancer
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Fig. 3. Cytotoxic effect of 5-fluorouracil (5-FU) alone and/or in combination with meloxicam in SNU-C5 (A) and SNU-C5/5FUR (B). 3-(4, 
5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide assay was used to analyze cell viability.
Fig. 4. Expression patterns of vascular endothelial growth factor 
(VEGF) mRNA in SNU-C5 and SNU-C5/5FUR at basal state and 
after treatment of meloxicam (10, 100 and 500 μM) for 24 hours by 
transcription-polymerase chain reaction method.
DISCUSSION
The present study demonstrates that the expressions of 
COX-2, PGE2, and VEGF were up-regulated in the 5-FU re-
sistant colon cancer cells rather than in the parental cells. 
Although meloxicam, a COX-2 inhibitor, showed little an-
titumor effect on both cells, it was found to have an an-
ti-angiogenic effect by down-regulating VEGF mRNA lev-
els in the 5-FU resistant colon cancer cells, but not in the 
parental cells. The expressions of TS (thymidylate syn-
thase) and DPD, which have been suggested to be in-
volved in 5-FU resistance, were not found to be sig-
nificantly changed by cDNA microarray analysis (data not 
shown). It has been suggested that wild type p53 sig-
nificantly improves response to 5-FU in vitro and in vivo 
[19,20]. In the present study, we used the colon cancer cell 
line, SNU-C5, and its 5-FU resistant derivative, the SNU- 
C5/5FUR cell line. It is known that p53 is mutated and 
non-functional in SNU-C5 cells [21]. 
It is known that COX-2 is induced by a variety of stim-
uli, such as, oncogenes (HER-2/neu), growth factors 
(EGF), tumor promoters (phorbol esters and bile acid), 
and chemotherapy [12]. Moreover, microtubule- interfer-
ing agents (paclitaxel, vincristine, etc) are known to induce 
COX-2 in cancer cells [22,23]. However, it has not been de-
termined as to whether COX-2 is induced by 5-FU in 5- 
FU-resistant cancer cells. It has been reported that COX-2 
mRNA expression is increased by 5-FU alone or in combi-
nation in human solid tumors, e.g., esophageal, breast, 
ovarian, and colorectal tumors [24]. In addition, sig-
nificant increases in COX-2 expression have been reported 
in rectal cancer after preoperative chemoradiotherapy Cheol Hee Choi, et al.
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[25]. The present study also demonstrates that COX-2 and 
PGE2 levels are up-regulated in colon cancer cells with ac-
quired resistance to 5-FU (SNU-C5/5FUR cells), which 
suggests that COX-2 inhibitors play a beneficial role in 
overcoming the resistance of SNU-C5/5FUR cells to 5-FU.
Clinically, 5-FU is used as a primary, secondary or even 
tertiary chemotherapy in colorectal cancer (CRC). When 
used as a first line chemotherapy or adjuvant therapy, 5- 
FU is usually used in combination with folinic acid in 
CRC. On the other hand, in cases that experience recur-
rence after treatment with the regimen, 5-FU is used again 
in combination with oxaliplatin (FOLFOX regimen) or iri-
notecan (FOLFIRI regimen). Theoretically, in cases of re-
currence the effects of 5-FU are likely to be limited, and 
thus, some means of overcoming acquired resistance to 
5-FU is required.
Irie et al. [26] reported that celecoxib (a selective COX-2 
inhibitor) synergistically potentiates the antitumor effect 
of 5-FU in an IFN-gamma dependent manner in an in vivo 
study of colon cancer cells. Other reports suggested that 
NSAIDs could be the modulators of fluorouracil-based 
chemotherapy, especially in high COX-2 expressing tu-
mors, and that combined therapy with S-1 and a COX-2 in-
hibitor might hold promise for prophylaxis of liver meta-
stasis of colorectal cancer [27,28]. A similar finding was re-
ported for ultraviolet B-induced skin tumors in mice [15]. 
However, we did not find that meloxicam synergistically 
potentiates the antitumor effect of 5-FU in either a chemo-
naïve colon cancer cell line and in an acquired 5-FU re-
sistant colon cancer cell line.  
It is believed that neovascularization is required for a 
tumor to grow to ＞2 to 3 mm [29]. Chang et al. [30] re-
ported that PGE2 stimulates the expressions of angiogenic 
regulatory genes in mammary tumor cells isolated from 
COX-2 transgenic mice, which demonstrates that COX- 
2-derived PGE2 is a potent inducer of angiogenic switch 
during mammary cancer progression. In the present 
study, VEGF up-regulation was observed in SNU-C5/ 
5FUR cells, and this up-regulation was recovered adding 
meloxicam, a COX-2 inhibitor, which suggests that COX- 
2-derived PGE2 plays an important role in the angiogenic 
switching that occurs during the acquisition of 5-FU resist-
ance in colon cancer. Furthermore, the present study dem-
onstrates that meloxicam exerts an anti-angiogenic effect 
by inhibiting PGE2 synthesis at a dose of 10 μM, which is 
relatively compatible with therapeutic levels. However, 
we had one unexpected result, i.e., SNU-C5 cells (which 
are chemonaïve colon cancer cells) express little VEGF or 
COX-2 in the basal state, but these cells were found to ex-
press VEGF after meloxicam treatment. Similarly, Ueno et 
al. [31] reported that treatment with celecoxib (a COX-2 in-
hibitor) decreased VEGF serum levels immediately after 
treatment but later increased its levels in serum and plas-
ma in breast cancer patients. Thus further studies are re-
quired to determine how COX-2 inhibitors participate in 
VEGF production in cancer cells and tissues that do not ex-
press COX-2. 
In conclusion, the authors demonstrate that COX-2 de-
rived PGE2 is up-regulated and COX-2 inhibitor may have 
anti-angiogenic effect in the colon cancer cells resistant to 
5-FU. 
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